Inflarx NV (NASDAQ:IFRX) Short Interest Down 63.6% in June

Inflarx NV (NASDAQ:IFRX) was the target of a large drop in short interest in the month of June. As of June 15th, there was short interest totalling 941,700 shares, a drop of 63.6% from the May 15th total of 2,584,200 shares. Currently, 6.2% of the company’s stock are short sold. Based on an average daily volume of 1,380,000 shares, the days-to-cover ratio is presently 0.7 days.

Several analysts recently issued reports on IFRX shares. Svb Leerink downgraded shares of Inflarx from an “outperform” rating to a “market perform” rating in a research report on Wednesday, June 5th. JPMorgan Chase & Co. set a $69.00 price target on shares of Helmerich & Payne and gave the company a “buy” rating in a research report on Wednesday, June 5th. ValuEngine downgraded shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. BMO Capital Markets lifted their price target on shares of Dollarama from C$35.00 to C$45.00 and gave the company a “market perform” rating in a research report on Wednesday, June 5th. Finally, SunTrust Banks downgraded shares of Inflarx from a “buy” rating to a “hold” rating and reduced their price target for the company from $55.00 to $5.00 in a research report on Wednesday, June 5th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the stock. Inflarx has an average rating of “Hold” and an average price target of $15.72.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp bought a new position in Inflarx during the 3rd quarter valued at about $277,000. Vanguard Group Inc. lifted its holdings in Inflarx by 137.4% during the 3rd quarter. Vanguard Group Inc. now owns 162,460 shares of the company’s stock valued at $5,576,000 after purchasing an additional 94,020 shares during the last quarter. Polar Capital LLP lifted its holdings in Inflarx by 54.4% during the 4th quarter. Polar Capital LLP now owns 141,887 shares of the company’s stock valued at $5,160,000 after purchasing an additional 50,000 shares during the last quarter. Bank of America Corp DE bought a new position in Inflarx during the 4th quarter valued at about $657,000. Finally, RA Capital Management LLC lifted its holdings in Inflarx by 6.0% during the 4th quarter. RA Capital Management LLC now owns 2,085,089 shares of the company’s stock valued at $75,835,000 after purchasing an additional 117,241 shares during the last quarter. Institutional investors own 55.89% of the company’s stock.

NASDAQ:IFRX traded down $0.14 during trading hours on Friday, hitting $3.00. 4,847,210 shares of the company traded hands, compared to its average volume of 1,224,361. The business’s 50-day simple moving average is $6.54. Inflarx has a one year low of $2.80 and a one year high of $53.10. The firm has a market cap of $81.53 million, a P/E ratio of -2.14 and a beta of -1.52.

Inflarx (NASDAQ:IFRX) last issued its quarterly earnings data on Thursday, May 23rd. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.19. Research analysts predict that Inflarx will post -2.09 earnings per share for the current year.

Inflarx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

Read More: Cost of Capital Explained

Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.